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Derived from bile duct epithelia (BDE), secretion by liver cyst-lining epithelia is positioned to drive cyst expansion but the responsible ion flux
pathways have not been characterized. Cyst-lining epithelia were isolated and cultured into high resistance monolayers to assess the ion secretory
pathways. Electrophysiologic studies showed a marked rate of constitutive transepithelial ion transport, including Cl− secretion and Na+
absorption. Na+ absorption was amiloride-sensitive, suggesting the activation of epithelial sodium channels (ENaC). Further, both cAMPi and
extracellular ATP induced robust secretory responses. Western blotting and immunohistologic analysis of liver cyst epithelia demonstrated
expression of P2X4, a potent purinergic receptor in normal BDE. Luminometry and bioassaying measured physiologically relevant levels of ATP
in a subset of liver cyst fluid samples. Liver cyst epithelia also displayed a significant capacity to degrade extracellular ATP. In conclusion,
regulated ion transport pathways are present in liver cyst epithelia and are positioned to direct fluid secretion into the lumen of liver cysts and
promote increases in liver cyst expansion and growth.
© 2006 Elsevier B.V. All rights reserved.Keywords: Autosomal dominant polycystic kidney disease (ADPKD); Ussing analysis; Purinergic signaling; cAMP; Epithelial sodium channel1. Introduction
Cystic liver diseases are a source of significant morbidity and
mortality. Three genetic forms of liver cyst disease have been
identified, including autosomal dominant polycystic kidney
disease (ADPKD), polycystic liver disease (PCLD) and
autosomal recessive polycystic kidney disease (ARPKD)
[1,2]. Occurring in 1 in 800 individuals, ADPKD is the most
common and best understood of the liver cyst diseases. Liver
cysts begin as focal out pockets of cells from the intrahepatic
bile duct, detach from the parent duct to form an enclosed,
autonomous cysts and continue to enlarge. Grossly affected
livers have innumerable cysts that are readily visualized by CT
and MRI imaging, can individually exceed 5 cm in diameter
and, as a group, more than double the volume of the liver [3].
The overt clinical manifestations of ADPKD arise around the
fourth decade of life and stem from the compression of⁎ Corresponding author. Fax: +1 303 315 3507.
E-mail address: brian.doctor@uchsc.edu (R.B. Doctor).
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doi:10.1016/j.bbadis.2006.11.006neighboring organs, tissues and vasculature. Surgical proce-
dures, ranging from cyst fluid aspiration to liver transplantation,
represent the mainstay of therapy since there are currently no
alternative medical therapies available. Understanding the
molecular and cellular events that promote cyst expansion
may direct the development of mechanism-based therapies to
treat individuals with liver cyst disease.
ADPKD is caused by mutations in PKD1 or PKD2, the
genes that encode for polycystin-1 and polycystin-2. While loss
of function of the ADPKD gene products leads to the initiation
of liver cyst formation, the disease progression is markedly
heterogeneous. Genetic considerations, such as the site or type
of gene mutation, may influence the variability in the course of
the disease but epigenetic factors not directly associated with
PKD1 or PKD2 gene mutations contribute substantially to the
pathogenic heterogeneity [4]. Since ADPKD liver cysts are
fully enclosed, it has been postulated that fluid secretion into the
cyst lumen might increase intralumenal pressures, mechanically
stretch the lining epithelium, induce proliferation of the epi-
thelial cells and, consequently, promote cyst expansion. Such a
Fig. 1. Superficial cysts in liver from a cpk(+/−) mouse. The image is of a cystic
liver from a 12-month-old Balb/c cpk(+/−) mouse in a 100 mm plate. During the
initial year of life, cpk(+/−) mice develop large fluid-filled liver cysts (asterisks)
that initiate from the intrahepatic bile ducts and expand out of the body of the
liver (arrow). Pkd2(WS25/−) mice develop similar liver cysts in a similar time
course (not shown). The cells lining these superficial liver cysts were isolated,
cultured and studied for their secretory characteristics.
346 R.B. Doctor et al. / Biochimica et Biophysica Acta 1772 (2007) 345–354paradigm is supported by prior observations. Human liver cysts
have a positive lumenal pressure (16 to 40 cm H2O) sufficient to
result in epithelial cell stretching [5]. Stretching of alveolar
epithelial cells induces the release of interleukin-8 [6], a pro-
proliferative cytokine that is found at physiologic levels in
humanADPKD liver cyst fluid [7]. Finally, stretching ofMadin–
Darby canine kidney cells increases the proliferation index of the
epithelial cells [8]. Transepithelial fluid secretion is driven by the
vectorial movement of ions and solutes across an epithelium and,
consequently, the osmotic movement of water. Given the
potential for fluid secretion to drive the expansion of liver
cysts, the present study sought to directly measure the ion flux
pathways present in the liver cyst epithelium.
Normal intrahepatic bile ducts are lined by a simple epithelial
cell type termed cholangiocytes. Cholangiocytes, when appro-
priately mutated, give rise to liver cysts. Normal cholangiocytes
have two distinct Cl− secretory pathways to initiate the secretion
of a bicarbonate-rich fluid into bile. Under physiologic condi-
tions, the hormone secretin interacts with specific receptors on
the basolateral membrane of cholangiocytes to increase cAMPi
levels. Subsequently, increased cAMPi leads to PKA-dependent
activation of cystic fibrosis transmembrane conductance regula-
tor (CFTR) Cl− channels in the apical membrane. In human
ADPKD studies, the administration of secretin increases fluid
secretion into liver cysts [5], suggesting cAMP-mediated
secretory pathways are intact in ‘cystic’ cholangiocytes. In
‘normal’ cholangiocytes, autocrine/paracrine signaling by extra-
cellular ATP initiates a distinct Cl− secretory response. Binding
of ATP to purinergic receptors activates Ca2+-dependent Cl−
channels and initiates a robust and prolonged Cl− secretory
response. To date, the lack of available cellular models of liver
cyst epithelia has hampered the direct determination if cAMPi- or
ATP-mediated Cl− secretory pathways are present in ‘cystic’
cholangiocytes. To address this important point, ‘cystic’
cholangiocytes were isolated from two genetic mouse liver cyst
models and the ion transport characteristics in these epithelial
cells were measured. Molecular and biophysical observations
support the concept that cystic epithelial cells have a high basal
rate of Cl− secretion and Na+ absorption and retain a robust Cl−
secretory response to both cAMPi and extracellular ATP. Given
the potential contribution of secretion into the enclosed lumen of
liver cysts to drive expansion of these cysts, pharmacologic
targeting of the identified secretory pathways may represent an
attractive target for amelioration of pathologic liver cyst
expansion.
2. Materials and methods
2.1. Cpk(+/−) and pkd2(WS25/−) mice
Both Balb/c cpk(+/−) and C57/Bl6 pkd2(WS25/−) mice were utilized in the
present studies. The cpk gene encodes for the protein ‘cystin’, a protein that has
not been directly linked to a specific human disease. The pkd2 gene is a direct
homolog of PKD2 in humans, one of the two genes directly linked to ADPKD in
humans. Cpk(+/−) mice were bred and reared at the Indiana University School
of Medicine Animal Resource Center. Female cpk(+/−) mice (∼1 years of age)
were transferred to the University of Colorado Health Sciences Center (UCHSC)
Animal Care Facility prior to studies. These animals reproducibly form large,
fluid-filled liver cysts that appear detached from the bile duct system (Fig. 1).Breeding pairs of pkd2(+/−) and pkd2(WS25/+) mice were graciously provided
by Stefan Somlo (Yale University). The WS25 allele is sensitive to
recombination and either reverts back to the wild type allele or forms an allelic
knockout [9]. The temporal somatic loss of the second pkd2 allele in pkd2
(WS25/−) mice mirrors the ‘second-hit’ somatic mutation that is thought to
occur in humans with ADPKD. Pkd2(WS25/−) consistently form histologically
discernible liver cysts by 4 months of age [9] and large, fluid-filled liver cysts at
8–12 months of age. Wild type C57/Bl6 mice were used to harvest control tissue
for Western and Northern blotting. Animals were euthanized (150 mg
pentobarbital/kg body weight) and their livers removed under aseptic conditions
as approved by the UCHSC Institutional Care and Use Committee. All animals
received humane care as outlined by the National Institutes of Health in ‘Guide
for the care and use of laboratory animals’.
2.2. Development of cpk(+/−) and pkd2(WS25/−) liver cyst epithelial
cultures
Unless otherwise noted, media and reagents for epithelial cell cultures were
obtained from Gibco-Invitrogen (Carlsbad, CA). Cpk(+/−) and pkd2(WS25/−)
liver cyst wall epithelial cells were isolated and cultured from superficial cyst
wall explants. Blocks (∼5 mm×5 mm) of cyst wall tissue were removed from
superficial liver cysts and finely minced under sterile conditions. The minced
tissues were seeded atop a ∼3 mm slab of rat tail collagen in cholangiocyte
growth medium (Dulbecco's modified Eagles medium/F12 media, 5% fetal
bovine serum (Hyclone; Logan, UT), 2 mM glutamine, 1% non-essential amino
acid solution, 1% lipid concentrate, 1% vitamin solution, 393 ng/ml
dexamethasone (Sigma-Aldrich; St. Louis, MO), 25 ng/ml epidermal growth
factor (Upstate Biologicals; Lake Placid, NY), 30 μg/ml bovine pituitary extract
(Upstate Biologicals; Lake Placid, NY), 3.4 μg/ml triiodothyrodine, 1% insulin–
transferrin–Se, 0.4 μg/ml forskolin (Sigma-Aldrich; St. Louis, MO), 50 μg/ml
soybean trypsin inhibitor). Epithelial cells were allowed to grow out from
minced tissue and were passaged as small epithelial islands by digesting away
the underlying collagen bed (1 mg/ml collagenase, 2 mg/ml dispase; 60 min at
37 °C). The complete enrichment of epithelial cells from cpk(+/−) (termed HL-
cpk cells) and pkd2(WS25/−) (termed pkd2 cells) was evaluated by light
microscopy, electron microscopy, Western blotting and electronic voltage-ohm
meter/Ussing analysis of transepithelial resistance.
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assay the expression of proteins in normal cholangiocytes. This was done by
collagenase digestion. Briefly, the portal vein was cannulated and the liver
perfused with collagenase (M.M. mg/ml in DMEM; 37 °C; gassed with 95%O2/
5% CO2; 45 min). After livers became translucent, hepatocytes were shaken free
from the biliary tree; the biliary tree was then further digested while shaking in
collagenase solution. Additional hepatocytes were then teased from the biliary
tree and the biliary tree was solubilized in 5×PAGE buffer (5% sodium dodecyl
sulfate, 25% sucrose, 50 mM Tris–HCl, 5 mM ethylenediamine tetraacetic acid
(EDTA), 0.2 M dithiothreitol; pH 8.0; Complete Protease Inhibitor II (Roche;
Mannheim, Germany)). Western blotting of ezrin and bile salt export protein
(BSEP) were used as marker proteins for cholangiocytes and hepatocytes,
respectively and used to assess bile duct enrichment.
Normal rat cholangiocytes (NRC) cells were used to bioassay human liver
cyst fluid. NRC cells were initially isolated by the LaRusso laboratory [10] and
were cultured on collagen slabs and passaged in cholangiocyte growth medium,
as previously described [11].
2.3. Electron microscopy of liver cysts and cultured liver cyst
epithelial cells
For electron microscopy (EM), tissues were fixed, processed and examined
as previously described [12]. For native liver cysts, superficial cyst walls were
trimmed from the cpk(+/−) and pkd2(WS25/−) livers and immediately
immersed in EM fixative (2% glutaraldehyde, 2% sucrose, 100 mM cacodylate;
pH 7.4). Cultured cpk(+/−) and pkd2(WS25/−) liver cyst epithelial cell
monolayers were prepared similarly. Following >60 min of fixation, these
tissues were post-fixed in 1% osmium, dehydrated in ethanol, embedded in
Epon812, stained with uranyl acetate and lead citrate and viewed by
transmission electron microscopy.
2.4. Western blot analysis
Western blot analysis was performed as previously described [13]. Briefly,
HL-cpk cells, pkd2 cells or mouse liver tissues were solubilized in 5×PAGE
buffer, separated on a 4%–14% gradient polyacrylamide gel, transferred onto
nitrocellulose and probed with primary antibodies, labeled with peroxidase-
tagged secondary antibodies and detected by enhanced chemiluminescence.
Primary antibodies were directed against actin (1:5,000 dilution; Calbiochem;
San Diego, CA), ezrin (1:100 dilution; NeoMarkers; Temecula, CA), pan-
cytokeratin (1:100 dilution; Sigma-Aldrich; St. Louis, MO), P2Y2 (1:300
dilution; Sigma Chemicals; St. Louis, MO), P2Y4 (1:300 dilution, Sigma
Chemicals; St. Louis, MO) or P2X4 (1:100 dilution; Alamone Labs; Jerusalem,
Israel).
2.5. Northern blotting
Northern blotting was performed as previously described [14]. Briefly, 20 μg
of total RNA from HL-cpk cells or mouse kidney (positive control) was
separated on a 1% agarose-formaldehyde gel and transferred onto a nylon
membrane (MSI). Probes against ENaC-αwere generated by random priming of
cDNA generated with ENaC-α primers ((Sense: CAAGACCCTTGTCCTCCT-
CAG; Antisense: GATGTTGAGGCTCACTGGCTAG), DecaPrimeII, Ambion;
Austin, TX) and spiked with 32P-dCTP. Membranes were blocked, probed and
washed prior to detection by film exposure.
2.6. Immunofluorescence staining
Human and pkd2(WS25/−) mouse liver cyst wall were subjected to
immunostaining and fluorescence analysis as previously described [13]. Briefly,
portions of the cyst wall were excised, fixed in 3% paraformaldehyde for 30+
min, embedded in OCT compound (Torrence, CA), frozen in liquid nitrogen,
cryosectioned (6 μm), blocked, stained with antibodies against P2X4 (1:100
dilution; Alamone Labs; Jerusalem, Israel), counterstained with FITC-labeled
secondary antibody and imaged for immunofluorescence (Nikon DiaPhot with
Diagnostics Instruments CCD camera). Control sections were incubated with
non-immune serum prior to counter staining with FITC-labeled secondaryantibody. The black level and sensitivity of detection were set such that these
control sections appeared black. Consequently, all fluorescence detected above
the black level in the paired sections that received P2X4 Ab is specific to that
antibody.
2.7. Ussing chamber analysis of epithelial monolayers
Transepithelial ion currents were measured across HL-cpk and pkd2
monolayers by Ussing chamber analysis, as previously reported [11]. Briefly,
monolayers were grown to confluence on semi-permeable, collagen-coated
PTFE membrane supports (Costar-Corning; Corning, NY) and allowed to
develop between 10 and 14 days following seeding. Monolayers were mounted
in the Ussing chamber in an extracellular buffer (E-buffer; 140 mMNaCl, 4 mM
KCl, 1 mM CaCl2, 1 mM KH2PO4, 10 mM HEPES, 10 mM glucose; pH 7.35;
295–300 mosM). Following a 10 min equilibration period, monolayers with
transepithelial resistances >1,000 Ω cm2 and basal short-circuit currents (Isc)
between 10 and 40 μAmps were used in the studies. When exchanging
solutions, the chamber solutions were exchanged with 10 times the chamber
volume of the desired solution. Colorimetric analysis showed this had a >99.5%
exchange efficiency. Low Cl− solutions were prepared by substituting Na–
gluconate for NaCl. Presented studies retained 5 mM chloride to stabilize the
Ag–AgCl electrode signal. Sodium was removed from the apical chamber
solution by substituting Tris–chloride for NaCl. cAMP-dependent Cl− secretion
was activated by the addition of 500 μM 8-cpt-cAMP and 450 μM 3-isobutyl-1-
methylxanthine (IBMX). Purinergic receptor-dependent ion secretion was
activated by the addition of 100 μM ATP to the apical chamber. Amiloride
was added to the apical chamber to evaluate epithelial Na+ channel (ENaC)
activity. An amiloride dose–response included 0.1 μM, 1 μM, 10 μM and
100 μM added to the apical chamber. Amiloride addition to the basal chamber
had no effect on Isc levels from HL-cpk cells (data not shown).
2.8. Measurements of ATP concentrations
The concentration of ATP was measured in liver cyst fluid samples and in
culture media by a luciferin-luciferase (L-Lase) assay as described by the
manufacturer (Promega; Madison, WI). Briefly, liver cyst fluid samples and
epithelial cell culture media were collected, immediately frozen in liquid N2 and
stored at −80 °C until assayed. For ATP degradation studies, the cell culture
media were initially spiked with 1 μM ATP and the rate of ATP loss was
measured. In the ATP assay, 10 μl of sample or ATP standards and 200 μl L-Lase
buffer were added to a clear 0.5 ml PCR tube. These tubes were placed inside a
7 ml scintillation vial and counted in a scintillation counter on single photon
mode (Beckman LS6000; Fullerton, CA).
2.9. Statistical analysis
The quantitative results are presented as mean±SEM. As noted in the text,
statistical analyses included t-tests and analyses of variance. Statistical
significances between groups were denoted when p<0.05.3. Results
3.1. Development of the mouse liver cyst cell lines
Fig. 1 shows a notable example of the liver cysts that
develop in livers of cpk(+/−) and pkd2(WS25/−) mice. In pkd2
(WS25/−) mice, all animals develop discernible liver cysts after
4 months [9]. At 12 months, the liver weight as a percentage of
body weight in male pkd2(WS25/−) mice were markedly
greater than wild type animals (pkd2(+/+): 4.8±0.2% (n=12);
pkd2(WS25/−): 21.0±4.8% (n=12); p<0.01). In extreme
examples, the livers from grossly affected animals 12 months
of age or older exceeded 50% of the total body weight. The wall
tissue from superficial cysts was isolated, minced and seeded on
Fig. 2. HL-cpk and pkd2 cells in culture retain characteristics of cyst wall
epithelia. (A) Transmission electron microscopy shows cpk(+/−) liver cyst
lining epithelia retain the morphologic features of normal cholangiocytes. Upper
panel shows native liver cyst epithelial cells; lower panel shows cultured liver
cyst epithelial cells (bars=1 μm). Morphologic features include a cuboidal
epithelium with short apical microvilli and electron dense junctional complexes.
Pkd2(WS25/−) liver cyst epithelia had similar histologic features (data not
shown). (B) Western blotting shows HL-cpk cells, from cpk(+/−) liver cysts, and
pkd2 cells, from pkd2(WS25/−) liver cysts, express epithelial cell and
cholangiocyte-specific marker proteins. A pan-cytokeratin Ab (pan-CK, an
epithelial cell marker) readily detected cytokeratins in the lysates. Ezrin, a
cholangiocyte-specific protein in liver, was readily detected in the HL-cpk and
pkd2 lysates. Ezrin is weakly detected in whole liver lysates since cholangiocytes
constitute <4% of the liver cell mass. Actin served to approximate relative
protein loading.
Fig. 3. HL-cpk monolayers secrete Cl− and absorb Na+ under basal conditions.
Cells in monolayer culture were mounted in an Ussing chamber and Isc was
measured under voltage clamp conditions (0 mV). (A) Substitution of Na+-
gluconate for NaCl in the basal chamber resulted in a marked decrease in the Isc
under basal conditions. A residual amount of chloride (5 mM) was required for
signal stabilization and precluded accurate quantitation of the basal Cl− efflux.
(B) Complete exchange of Tris for Na+ in the apical chamber resulted in a
pronounced drop in the Isc across HL-cpk cells (−55±10 μA; n=4). Both
currents were restored upon reintroduction of Cl− and Na+, respectively.
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monolayer. Transmission electron microscopy of HL-cpk liver
cyst epithelial cells showed they retained ultrastructural features
of native cpk(+/−) liver cyst epithelia (Fig. 2A). These features
include a short (<10 μm), cuboidal epithelium with small
abundant apical microvilli and well-developed junctional
complexes at the apical pole. Western blot analyses for
cytokeratins and ezrin in HL-cpk and pkd2 cells were both
positive (Fig. 2B). Cytokeratins are distinctly expressed in
epithelial cells; ezrin is expressed in cholangiocytes (intrahe-
patic bile duct epithelium) but not hepatocytes, the secondepithelial cell type in liver. Therefore, as anticipated, cholan-
giocytes are the likely progenitor cell of the liver cyst lining
epithelium in these animals. Western blotting for vimentin, a
marker protein for mesenchymal cells, was positive in some
samples (data not shown), suggesting there may be some
fibroblast contamination in these primary cultures. However,
cultured HL-cpk and pkd2 epithelial cells formed an electrically
‘tight’ monolayer with transepithelial resistances >1000 Ω cm2
and the presence of any fibroblasts did not appear to affect
epithelial cell functions (see below). Finally, HL-cpk mono-
layers secrete a similar profile of cytokines as the native cpk(+/
−) liver cyst epithelium (data not shown). Collectively, these
findings indicate the non-transformed HL-cpk and pkd2 cells in
culture originate from the bile duct epithelium (i.e. cholangio-
cytes) and retain general characteristics of the parent cell type.
3.2. HL-cpk epithelia exhibit basal levels ofCl− secretion andNa+
absorption
Fluid within enclosed liver cysts has a positive hydrostatic
pressure [5], consistent with active secretion into the cyst lumen
by the cyst-lining epithelium. Transepithelial fluid secretion is
generally driven by the vectorial movement of ions across the
epithelium and a consequent osmotic flux of water. Accord-
ingly, ion substitution studies were performed to determine if
appreciable levels of Cl− and Na+ ion transport were present in
liver cyst epithelia. In Fig. 3A, Cl− in the basal chamber of HL-
cpk cells was reduced from 140 mM to 5 mM by substituting
Na–gluconate for NaCl. This substitution resulted in a marked
drop in the short-circuit current; values were restored following
reintroduction of Cl−. The Cl− substitution studies required a
Fig. 4. HL-cpk monolayers have an amiloride-sensitive current under basal
conditions. The potential contribution of the epithelial Na+ channel (ENaC) to the
basal Na+ absorption current was evaluated. (A)Northern blotting found ENaC-α
mRNAwas present in HL-cpk cells at similar levels as found in mouse kidney.
Equal amounts of mRNA (20 μg) were added in both lanes. (B) The addition of
10 μM amiloride to the apical chamber resulted in a significant decrease in the
basal Isc (−14±2 μA; n=10) (C) A dose–response analysis showed that 0.1 μM
amiloride induced a modest decrease in the basal Isc (−7±3 μA; n=3) while
1 μM amiloride (−13±2 μA; n=8) and 10 μM (−14±2 μA; n=10) amiloride
induced a more robust inhibition. High dose amiloride (100 μM; −10 μA; n=2)
also inhibited the basal current.
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precise basal Cl− current was not quantitated. However, the
observations indicate HL-cpk cells have marked vectorial Cl−
transport (basal to apical) that contributes importantly to the
observed high Isc under basal conditions.
Similarly, apical Na+ substitution in HL-cpk cells resulted in
a pronounced drop in the Isc (Fig. 3B), indicating that
electrogenic Na+ absorption (55±10 μAmps; n=4) contributes
significantly to the basal Isc. In many epithelial cell types, the
epithelial Na+ channel (ENaC) contributes to apical Na+
absorption. In normal cholangiocyte cells and monolayers,
however, ENaC activity has not been described and amiloride
has no effect on basal Isc values in normal rat cholangiocytes
(data not shown). Lack of an effective ENaC antibody
precluded the direct assessment of ENaC expression in HL-
cpk cells but RT-PCR (data not shown), Northern blotting and
Ussing analysis indicate ENaC is expressed and active in liver
cyst epithelial cells (Fig. 4). Northern blotting of HL-cpk
mRNA readily detected ENaC-α message at levels similar to
those found in mouse kidney tissue. Amiloride added to the
apical chamber induced a marked decrease in the basal Isc of
HL-cpk cells. At 0.1 μM amiloride, the inhibition was relatively
weak (−7±3 μA; n=3) but was more robust and significantly
inhibited at 1 μM (−13±2 μA; n=8; p<0.01) and 10 μM
amiloride (−14±2 μA; n=10; p<0.01). Application of
amiloride (10 μM) to the basal chamber of HL-cpk monolayers
failed to alter the basal Isc level (data not shown). These
findings indicate ENaC is expressed in cyst epithelia, is
constitutively active and accounts for a significant portion of
the basal Isc in HL-cpk cells.
3.3. HL-cpk cells retain cAMPi- and ATP-mediated secretory
responses
In normal cholangiocytes, elevated cAMPi and extracellular
ATP stimulates Cl− secretion [15–19]. To assess if ‘cystic’
cholangiocytes retain these regulated secretory pathways, mono-
layers were exposed to agonists during measurement of Isc (Fig.
5). In HL-cpk monolayers, increased cAMPi (500 μM 8-cpt-
cAMP; 450 μM IBMX) induced an increase in the Isc (15±5 μA;
n=4; p<0.05). Likewise, extracellular ATP stimulated an
increase in the Isc (40±9 μA; n=4; p<0.05). Thus, in parallel
with native cholangiocytes, regulated secretory pathways are
present in ‘cystic’ cholangiocytes and could drive fluid secretion
into the liver cyst lumen.
3.4. Pkd2(WS25/−) liver cyst epithelia also retain regulated
secretion characteristics
To determine if the functional properties in HL-cpk(+/−)
liver cyst epithelia are present in other liver cyst models, liver
cyst epithelial cells were isolated from pkd2(WS25/−) mice and
tested for their responses to amiloride, 8-cpt-cAMP and
extracellular ATP. Ussing chamber analysis of pkd2 monolayers
had a sustained lumen-negative electrical potential and a
positive Isc. Application of amiloride to the apical membrane
decreased the basal Isc (−5.0±1.4 μA; n=3) and incubationwith either 8-cpt-cAMP/IBMX or extracellular ATP induced
marked secretory responses (Fig. 6). Thus, liver cyst epithelia
from pkd2-mutated mice also perform robust basal and
regulated transepithelial ion transport.
3.5. Cystic epithelia express P2X4 purinergic receptors
These above findings indicate that liver cyst epithelial cells
exhibit a robust secretory response to extracellular ATP. Normal
cholangiocytes have a complex purinergic receptor profile
[15,20,21]. In normal cholangiocytes, P2Y2, P2Y4 and P2X4
are the most prominent ATP receptor types and P2X4 receptors
Fig. 5. HL-cpk monolayers have cAMP-induced and ATP-induced currents. In
normal cholangiocytes, cAMPi and extracellular ATP induced Cl
− secretory
responses [11,15,19]. (A) Likewise, HL-cpk cells displayed an increased Isc
(peak: 15±5 μA; n=4) when cAMPi was elevated (500 μM 8-cpt-cAMP;
450 μM IBMX). (B) HL-cpk cells also displayed an increased Isc (peak: 40±
9 μA; n=4) when 100 μMATP was added to the apical media. The pattern of the
HL-cpk response to ATP had two components, an immediate, short-lived
increase in Isc followed by a slower, prolonged increase.
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response [15]. The relative expression of these three purinergic
receptors in liver cyst epithelial cells was evaluated by Western
blotting. The expression level was compared to levels in whole
liver, enriched ‘normal’ bile ducts, liver cyst wall tissue and
cultured liver cyst epithelial cells. The enrichment of the ‘normal’Fig. 6. Pkd2(WS25/−) cells also have secretory responses. Similar to HL-cpk
liver cyst epithelial cells, liver cyst epithelial cells from pkd2(WS25/−) mice
(pkd2) showed a similar short-circuit current responses in to apical amiloride,
increased cAMPi and extracellular ATP.bile ducts was demonstrated by blotting for ezrin (cholangiocyte
marker protein) and BSEP (hepatocyte marker protein). Whole
liver (∼80% hepatocyte; ∼3% cholangiocyte), enriched
hepatocytes had marked levels of BSEP and little ezrin signal.
Conversely, the enriched bile ducts (i.e. cholangiocytes) had
comparatively little BSEP signal by marked levels of ezrin (Fig.
7A). Consistent with previous reports [15,20,21], ‘normal’ bile
ducts expressed P2Y2, P2Y4 and P2X4 protein (Fig. 7B).
Isolated liver cyst wall tissue had more modest but detectable
expression of all three purinergic receptor types. The relative
distribution of these three proteins in the epithelial, endothelial
and mesechymal cells of the cyst wall was not specifically
determined.Cultured pkd2 cells, however, hadminimally detectedFig. 7. Liver cyst epithelia express purinergic receptors. Normal cholangiocytes
express P2Y2, P2Y4 and P2X4 purinergic receptors [15,19,21]. The expression
of these receptors was evaluated in liver cyst epithelial cells. (A) Normal bile
ducts were enriched from mouse liver to serve as a positive control. Using BSEP
and ezrin for markers of hepatocytes and cholangiocytes (i.e. bile ducts),
respectively. Compared to liver and hepatocytes (Hep), isolated bile ducts (Duct)
had significant enrichment of ezrin and de-enrichment of BSEP (B) Normal bile
ducts (Duct) expressed P2Y2, P2Y4 and P2X4. Relative expression of each of
these was diminished in liver cyst wall tissue (Cyst), comprised of epithelial
cells, endothelial cells and mesenchymal cells. Isolated liver cyst epithelial cells
(pkd2) also showed weak expression of P2Y2 and P2Y4 but had robust
expression of P2X4. Actin served as a loading control. (C) This robust
expression in pkd2 cells was mirrored in HL-cpk cells. (D) Immunofluorescence
staining for P2X4 demonstrated expression both in native mouse pkd2(WS25/−)
liver cyst epithelia (upper panel; bar=15 μm) and in human ADPKD liver cyst
epithelial cells (lower panel; bar=10 μm). As in normal cholangiocytes, P2X4 is
expressed broadly across the cell membrane domains. The sectioning across the
cyst lumen in the human liver cyst (lower panel) shows P2X4 is present at the
apical membrane domain.
Fig. 8. ATP levels aremarkedly variable in disparate liver cysts. Directmeasurement
and bioassay of liver cyst fluid reveals ATP is present in liver cyst fluids but their
concentrations are markedly variable. (A) In pkd2(WS25/−) liver cyst fluid
samples, ATP ranged from 2,660 nM to 0 nM. The majority of samples (21 of 26)
were under 100 nMand below theKm for purinergic receptors. Of the 26 samples
measured, two samples were near the Km for purinergic receptors and three
samples were significantly greater than the Km for purinergic receptors. Three
samples from cpk(+/−) mice had concentrations ranging from 49 nM to 197 nM.
(B) Bioassay of human liver cyst fluid did not elicit any change in the Isc of NRC
cells in 4 of 5 samples tested (upper tracing). One of 5 samples, however, elicited
an increased Isc that was similar in magnitude and duration to ATP responses
(middle tracing). Pre-treatment of the positive cyst fluid sample with apyrase, an
ATP degrading enzyme, abolished the fluid-evoked increase in Isc (lower
tracing). ATP was added to the apical chamber at the end of each run to ensure
monolayer responsiveness.
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parallel with pkd2 cells, P2X4 is also readily detected in HL-cpk
cells (Fig. 7C). The expression of P2X4 protein in mouse liver
cyst cultures was confirmed by immunofluorescence with P2X4
observed in native liver cyst-lining epithelial cells from both
mouse pkd2(WS25/−) and human ADPKD (Fig. 7D). The cross
section through human liver cysts shows that P2X4 is broadly
expressed in the cyst lining epithelial cells including expression
at the apical domain. These observations demonstrate, at a
minimum, that P2X4 purinergic receptors are expressed and
positioned in the cystic epithelial cells and to mediate the
secretory response to ATP. To begin to evaluate whether these
pathways are operative in vivo, ATP concentrations in liver cyst
fluids were measured.
3.6. Physiologic ATP concentrations in liver cysts
Secretion of ATP into enclosed cyst lumens could permit the
accumulation of ATP to levels that activate purinergic receptors.
The Km of ATP for the P2Yand P2X families of receptors ranges
from 100 to 500 nM. Accordingly, ATP concentrations were
assayed in liver cyst fluids aspirated from cpk(+/−) and pkd2
(WS25/−) mice and found to be markedly variable. In three cpk
(+/−) samples, ATP levels ranged from 49 to 197 nM (Fig. 8A).
In pkd2(WS25/−) liver cyst fluid, the majority of samples also
hadATP concentrations below 200 nM. Three samples, however,
had ATP levels well above the Km for purinergic receptors
(710 nM; 1,616 nM; 2,660 nM). Thus, in a minority of liver cyst
fluid samples, ATP was present at physiologic/supraphysiologic
levels.
Bioassaying of five human liver cyst fluid samples for ATP-
mediated secretory responses was consistent with this observa-
tion. In these studies, normal rat cholangiocyte (NRC)
monolayers were mounted in an Ussing chamber and the buffer
in the apical chamber (18 ml) received 2 ml human liver cyst
fluid. Four of the five samples tested failed to elicit a change in
the short circuit current. One sample elicited an Isc response that
was similar in magnitude and duration as an ATP-induced
response (Fig. 8B). Pre-treatment of the ‘positive’ cyst fluid
with apyrase, an enzyme that degrades ATP, ablated the
secretory response. Taken together, these observations suggest
that physiologically important concentrations of ATP are
present in a subset of liver cyst fluids.
3.7. HL-cpk cells have significant extracellular nucleotidase
activity
ATP concentrations in cyst fluids reflect the balance of
release and degradation of ATP at the time of sampling. To
determine if the observed variability in cyst fluid ATP levels
was related to the capacity of cyst epithelia to degrade
extracellular ATP, liver cyst epithelial cells were grown to
confluence, the media (5 ml) was spiked with exogenous ATP
(final concentration of ∼1 μM) and the rate of degradation was
followed over time (Fig. 9). In the presence of serum and
absence of cells, there was a small but measurable loss of ATP
over time. Thus, studies were performed using ATP-spikedserum-supplemented media or PBS, each with or without cells.
The inclusion of pkd2(WS25/−) cell monolayers resulted in a
rapid and robust loss of ATP (Fig. 9A). Quantitative analysis
showed only 7±2% of the initial ATP remained after 15 min
(n=5; p<0.01) and only 1±1% of the initial ATP remained
after 30 min (n=5; p<0.01; Fig. 9B). Similarly, <1% of the
initial ATP was detectable after 30 min in HL-cpk (n=1) and
NRC (n=1) monolayers. Thus, liver cyst epithelial cells retain
Fig. 9. Extracellular ATP is rapidly degraded by liver cyst epithelia. The capacity
of pkd2 liver cyst epithelia to degrade extracellular ATPwasmeasured. (A) In the
absence of cells, incubation of ATP in either PBS (open circles) or supplemented
media (open squares) showed little decrease in ATP over 15 min. In contrast, the
rate of ATP degradation was markedly increased in the presence of pkd2
monolayers. Values were similar with PBS covering pkd2 monolayers (closed
circles) or supplemented media covering pkd2 monolayers (closed squares).
Shown is a representative experiment. (B) Quantitative analysis (n=5) found
extracellular ATP levels were degraded to 7±2% (p<0.01 vs. 0 min) of initial
concentrations after 15 min and to 1±1% (p<0.01 vs. 0 min) of initial
concentrations after 30min of incubation. In bothHL-cpk (n=1) andNRC (n=1)
monolayers, ATP was similarly degraded to ≤5% and 1% of the initial
concentration after 15 min and 30 min of incubation, respectively (data not
shown).
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temporally moderate purinergic signaling of the cyst lining
epithelium.
4. Discussion
4.1. Extragenetic factors impact liver cyst disease severity
ADPKD, the leading cause of human kidney and liver cyst
formation, is a ‘molecular recessive’ disease that is linked to
mutations in PKD1 and PKD2. ADPKD associated withmutations in PKD2 has a later onset and milder course than
that associated with mutations in PKD1 [22]. Further, the
position of the mutation within the gene and susceptibility to the
second somatic mutation may influence disease expression [23].
Beyond this, however, other modifier genes and environmental
factors largely dictate disease severity [24]. The pathology in
rodent renal cyst models is impacted by epigenetic factors and
studies of human sibships and monozygotic twins strongly
corroborate the contribution of modifier genes [25–28]. Many
of the concepts and hypotheses in the present liver cyst study
stem from the study of ADPKD renal cyst disease. Identifying
the pivotal epigenetic factors that specifically promote ADPKD
liver cyst growth is particularly poignant since the clinical
sequelae of cystic liver disease are largely determined by the
increases in liver volumes.
Liver cysts originate from mutated cholangiocytes that
proliferate and emerge from the intrahepatic bile duct. In
humans, the intrahepatic bile duct epithelium normally
constitutes 2–4% of the liver cell mass but contributes up to
40% of the total bile volume in a regulated manner. If ‘cystic’
cholangiocytes retained this robust secretory capacity, the fluid
secretion into the lumens of enclosed liver cysts would likely
increase the lumenal pressure and result in epithelial cell
stretching. In culture models, epithelial cell stretching initiates
cytokine release and induces cell proliferation [8,29]. Interest-
ingly, interleukin-8 is a potent proliferative cytokine that is
specifically released during epithelial cell stretching and is also
concentrated to physiologic levels in human ADPKD liver cyst
fluid [6,7]. Consequently it was hypothesized that fluid
secretion into liver cysts promotes stretching of the cyst lining
epithelium, causing the release of cytokines into the cyst fluid
that then signal an acceleration of cyst growth. The present
studies begin to test this hypothesis by evaluating if basal and
regulated secretory pathways are present in liver cyst epithelial
cells.
4.2. Epithelial sodium channel activity is elevated in liver cystic
epithelial cells
In pulmonary epithelial monolayers, ENaC activity mediates
net fluid absorption and controls the volume of the apical fluid
layer [30]. In renal distal tubules, aldosterone moderates ENaC
distribution and activity at the apical membrane of renal
principal cells to control Na+ reabsorption and urinary Na+ loss
[31]. In autosomal recessive polycystic kidney disease
(ARPKD), ENaC is dysregulated with higher levels of
amiloride-sensitive Na+ absorption; this activity is inhibited
by apical EGF receptor activation [32–34]. ENaC expression
and function in cholangiocytes has not been reported and
amiloride-sensitive Isc was not observed in normal rat
cholangiocytes (data not shown). In liver cyst epithelial cells,
however, ENaC mRNA and amiloride-sensitive Isc was readily
detected (Figs. 4 and 6). Theoretically, this might represent an
adaptive response since increased apical ENaC activity would
increase Na+ absorption from the cyst lumen and thereby reduce
fluid pressure within liver cysts. In other epithelia, ENaC
activity is regulated by a variety of mechanisms, including
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probability. The complete characterization of these ENaC
regulatory pathways may elucidate a role for regulated ENaC
activity in normal bile duct function, provide insight into the
molecular mechanisms of cyst expansion and unveil new
treatment strategies to blunt fluid secretion into liver cysts.
4.3. cAMP-mediated secretory pathway persists in liver cyst
epithelia
Treatment of ADPKD renal monolayers with cAMP agonists
induces a secretory response [35] and the CFTR Cl− channel
appears to contribute significantly to the cAMP-mediated
secretory response [36,37]. This includes cell proliferation
assays in three dimensional renal cell cultures where CFTR-
mediated Cl− secretion is directly associated with renal cyst
growth [38,39]. In humans, an ADPKD family with concurrent
CFTR gene mutations had a milder ADPKD disease phenotype,
suggesting control of cAMPi-mediated secretion can influence
ADPKD disease severity [40]. cAMPi-mediated, CFTR-depen-
dent Cl− secretion plays a central role in regulated secretion in
bile ducts [16,17]. A number of gut hormones positively (e.g.
secretin) and negatively (e.g. somatostatin) influence ductular
secretion by moderating cAMPi levels. In an in vivo human
ADPKD liver cyst study, administration of secretin resulted in
an increase in fluid secretion [5]. The present study corroborates
these findings at the cellular level by directly demonstrating that
liver cyst epithelial cells retain potent cAMPi-mediated
secretory responses (Figs. 5 and 6). In bile ducts, the pro-
secretory effects of secretin are inhibited by somatostatin.
ADPKD patients treated with the somatostatin analogue
octreotide exhibited slower rates of growth in renal volume
[41]. While the study did not evaluate hepatic cyst growth, the
known physiologic effects of somatostatin on ductular secretion
predict octreotide should be effective in inhibiting hepatic cyst
enlargement.
4.4. ATP-mediated secretory pathways persist in liver cyst
epithelia
Extracellular ATP is a potent stimulus for Cl− secretion in a
variety of epithelia including the intrahepatic bile duct [15,20].
The potential for ATP to drive lumenal fluid secretion and cyst
growth has been studied in ADPKD renal cysts. In a subset of
ADPKD renal cysts, ATP accumulates to physiologic levels
[42,43] and demonstrable ATP release from cultured ADPKD
renal cyst epithelial cells suggests the lining epithelium is the
source of ATP [43,44]. The presence of purinergic receptors on
renal cyst epithelial cells permits the secreted and accumulated
ATP to participate in autocrine/paracrine signaling [43,45]. The
potential significance of this autocrine/paracrine signaling axis
is demonstrated in 3D MDCK cell cultures where inhibition of
P2Y signaling blunts the growth of the MDCK cysts [46]. The
potential role of ATP-mediated Cl− secretion is further
advanced by the observation that polycystin-1, one of the two
proteins genetically linked to ADPKD, can moderate Ca2+ entry
into ATP-stimulated epithelial cells [47].Normal bile duct epithelial cells (i.e. cholangiocytes) also
secrete ATP across their apical membranes and express specific
purinergic receptor subtypes [15,18]. The purinergic signaling
axis is retained, at least in part, in ‘cystic’ mouse and human
cholangiocytes which express P2X4 receptors (Fig. 7) and have
robust secretory response to apical ATP (Figs. 5 and 6). ATP
signaling is likely not tonically activated since physiologic
levels of ATP were detected in a subset of mouse liver cyst
fluid samples (Fig. 8A) and a subset of human ADPKD liver
cyst fluid samples induced an ATP-dependent secretory
response from cholangiocytes (Fig. 8B). With a significant
capacity to degrade extracellular ATP (Fig. 9), ATP-directed
secretion by liver cyst epithelial cells likely occurs in liver cysts
when the rate of apical ATP release exceeds the rate of ATP
degradation and ATP accumulates to physiologically relevant
levels.
4.5. Controlling cystic fluid secretion may serve as a
therapeutic target
Collectively, these studies demonstrate, for the first time, that
liver cyst epithelial cells have substantial capacities for Cl−
secretion and Na+ absorption and retain a capacity to increase
vectorial ion fluxes in response to elevated cAMPi or extracellular
ATP. Since ADPKD liver cysts have a positive lumenal pressure
[5,48], it is attractive to speculate that additional fluid secretion
would increase lumenal pressure, causing epithelial cell stretch-
ing, cell proliferation and cyst expansion [6,8,29]. With no
medical therapies currently available for treating ADPKD liver
cyst disease, the present study suggests efforts to assess the effects
of inhibiting secretion on liver cyst growth and development of
the clinical manifestations of liver cyst disease are strongly
warranted.
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